Introduction: Bronchitis has a large share among respiratory pathology in children and accounts for about 1/4 of all recurrent and chronic respiratory diseases.  Bronchitis is one of the most common respiratory diseases in children. Children with recurrent bronchitis (RB) make up almost 30 % of all patients with respiratory diseases.  The prevalence of RB in children is 2.5 per 1000 children aged 1–15 years;  among children under 3 years of age, 2.3% are ill, preschoo l – 7.1  % and 2.6  % – school-age patients.  Today, recurrent bronchitis, according to the Order of the Ministry of Health of Ukraine, is defined as bronchitis, episodes of which recurrent  2-3 times a year and more often for 1–2 years on the background of acute respiratory viral infections (ARI). In children, frequent manifestations of RB lead to a decrease in the body’s defenses, suppression of immunity.  One of the drugs in such conditions is “Bronchomunal”.  It has an immunostimulatory effect on the body indirectly, by increasing the production of interleukins, namely IL-1, IL-6, IL-12, the production of antibodies against the main pathogens of acute respiratory viral infections.

Aim: The aim of our work was to study the effect of the drug “Bronchomunal” on the course of this pathology among children and the frequency of recurrences of bronchitis.

Materials and methods: Under observation were 38 preschool children with recurrent obstructive bronchitis, who were ill more than 3 times a year for this pathology and were hospitalized in the city children’s hospital in Sumy.  This group of children received traditional therapy according to the treatment protocol of the underlying disease and along with the drug immunomodulator – “Bronchomunal”.

Results: As a result of our observations, it was found that children who was along with traditional treatment during the exacerbation of the disease, as well as after discharge from the hospital received this drug for another week in an outpatient setting.  This drug contributed to faster clinical recovery of patients (reduced signs of obstruction, dry wheezing on auscultation over the lungs).  Such children after recovery felt well and shortened the period of re-consultation with a doctor about this disease.

Сonclusions: Thus, given the immunomodulatory effect of “Bronchomunal” on the body, by increasing the activity of phagocytes, T and B-lymphocytes, stimulating the synthesis of antibodies and cytokines, increasing the cytotoxicity of lymphocytes, it is advisable to use a long course of this drug in children diagnosed with recurrence. Therefore, we can assume that immunomodulatory  drugs are effective at all levels of the immune response, both in the acute phase of the disease and in long-term immunotherapy, especially in frequently ill children.